Dr Michelle Lawson

BSc, PhD, FHEA

School of Medicine and Population Health

School Director of Postgraduate Research

Senior Lecturer in Bone and Cancer Biology

Dr Michelle Lawson
Dr Michelle Lawson
Profile picture of Dr Michelle Lawson
m.a.lawson@sheffield.ac.uk
+44 114 215 9054
Office EU22, E Floor, The Medical School

Full contact details

Dr Michelle Lawson
School of Medicine and Population Health
Office EU22, E Floor
The Medical School
Beech Hill Road
Sheffield
S10 2RX
Profile

For enquiries please contact - SMPH-West-Operational@sheffield.ac.uk

I graduated from the University of Sheffield in 1997 with a BSc (Hons) in Molecular Biology. I obtained my PhD in 2000 from the University of Bristol, after conducting my research at the Institute of Animal Health, investigating the use of cytokines as DNA vaccine adjuvants.

In 2000 I began my research career in the field of bone biology at the University of Oxford. While there I developed various biomaterials for bone scaffolding and a novel technique to measure the bone binding affinities of bisphosphonates, drugs used in the prevention of bone disease.

In 2005 I moved back to the University of Sheffield where I worked in Professor Peter Croucher’s Bone Biology Group and my research involved looking at the effects of bisphosphonates in preclinical models of multiple myeloma. I also developed a novel microscopy technique to allow the visualization of single dormant cancer cells in bone. Together this research has led to the identification of several key molecules involved in the early stages of myeloma and its associated bone disease. I am currently a Senior Lecturer in Bone and Cancer Biology in the Department of Oncology and Metabolism and I lead the Sheffield Myeloma Research Team (SMaRT). My main research interests are myeloma-induced bone disease, dormant tumour cells, and the use of oncolytic adenoviruses to combat myeloma and lymphoma.

Current PhD opportunities:

  •  
Research interests

I have developed and established several preclinical murine models of myeloma to study therapeutic intervention in the early, mid and late stages of the disease. This has led to an increased understanding of the role of the bone marrow microenvironment and how it influences tumour growth and tumour cell dormancy. I am currently investigating the use of standard of care anti-myeloma drugs in combination with bone modulating agents to repair myeloma-induced bone disease; and using existing (standard of care therapies) or novel agents (oncolytic viruses) to target myeloma cells (proliferating and dormant) in the bone marrow microenvironment, with the aim of translating these findings into patients. I am currently collaborating with Theolytics to harness viruses to combat myeloma ().

Publications

Show: Featured publications All publications

Journal articles

  • Stewart G, Tazzyman S, Sun Y, Andrews RE, Harrison J, Lath D, Down J, Robinson G, Wang X, Muthana M , Chantry AD et al (2025) . Leukemia, 39(6), 1449-1463.
  • Evans H, Andrews R, Abedi FA, Sprules A, Trend J, Lovric G, Green A, Chantry A, Clarkin C, Brown J & Lawson M (2024) . JBMR Plus, 8(9).
  • Stewart G, Chantry A & Lawson M (2021) . Cancers, 13(22).
  • Andrews RE, Brown JE, Lawson MA & Chantry AD (2021) . Journal of Clinical Medicine, 10(17).
  • Müller LME, Migneco G, Scott GB, Down J, King S, Askar B, Jennings V, Oyajobi B, Scott K, West E , Ralph C et al (2021) . Journal for ImmunoTherapy of Cancer, 9(3).
  • Diaz-delCastillo M, Chantry AD, Lawson MA & Heegaard A-M (2021) . Seminars in Cell & Developmental Biology, 112, 49-58.
  • Crawford LJ, Campbell DC, Morgan JJ, Lawson MA, Down JM, Chauhan D, McAvera RM, Morris TC, Hamilton C, Krishnan A , Rajalingam K et al (2020) . Oncogene, 39(27), 5001-5014.
  • Green AC, Lath D, Hudson K, Walkley B, Down JM, Owen R, Evans HR, Paton‐Hough J, Reilly GC, Lawson MA & Chantry AD (2019) . Journal of Bone and Mineral Research, 34(12), 2311-2326.
  • Paton-Hough J, Tazzyman S, Evans H, Lath D, Down JM, Green AC, Snowden JA, Chantry AD & Lawson MA (2019) . Journal of Bone and Mineral Research, 34(5), 783-796.
  • Lawson MA, Ebetino FH, Mazur A, Chantry AD, Paton-Hough J, Evans HR, Lath D, Tsoumpra MK, Lundy MW, Dobson RLM , Quijano M et al (2017) . Journal of Bone and Mineral Research, 32(9), 1860-1869.
  • Lawson MA, McDonald MM, Kovacic N, Khoo WH, Terry RL, Down J, Kaplan W, Paton-Hough J, Fellows C, Pettitt JA , Dear TN et al (2015) . Nature Communications, 6.
  • Paton-Hough J, Chantry AD & Lawson MA (2015) . Bone, 77, 57-68.
  • Lawson MA, Paton-Hough JM, Evans HR, Walker RE, Harris W, Ratnabalan D, Snowden JA & Chantry AD (2015) . PLOS ONE, 10(3).

Book chapters

  • Holen I, Saleh L, Ottewell PD & Lawson MA (2022) , Bone Cancer (pp. 35-53). Elsevier
  • Edwards CM & Lawson MA (2022) , Bone Cancer (pp. 1005-1017). Elsevier
  • Green AC, Andrews RE & Lawson MA (2020) , Encyclopedia of Bone Biology (pp. 180-200). Elsevier
  • Holen I & Lawson MA (2015) , Bone Cancer Primary Bone Cancers and Bone Metastases Second Edition (pp. 503-518).

All publications

Journal articles

  • Stewart G, Tazzyman S, Sun Y, Andrews RE, Harrison J, Lath D, Down J, Robinson G, Wang X, Muthana M , Chantry AD et al (2025) . Leukemia, 39(6), 1449-1463.
  • Harrop R, Blount DG, Khan N, Soyombo M, Moyce L, Drayson MT, Down J, Lawson MA, O’Connor D, Nimmo R , Lad Y et al (2025) . Molecular Cancer Therapeutics, 24(1), 93-104.
  • Evans H, Andrews R, Abedi FA, Sprules A, Trend J, Lovric G, Green A, Chantry A, Clarkin C, Brown J & Lawson M (2024) . JBMR Plus, 8(9).
  • Hodgson K, Orozco-Moreno M, Goode EA, Fisher M, Garnham R, Beatson R, Turner H, Livermore K, Zhou Y, Wilson L , Visser EA et al (2024) . eBioMedicine, 104.
  • Diaz-delCastillo M, Palasca O, Nemler TT, Thygesen DM, Chávez-Saldaña NA, Vázquez-Mora JA, Ponce Gomez LY, Jensen LJ, Evans H, Andrews RE , Mandal A et al (2023) . The Journal of Neuroscience, 43(29), 5414-5430.
  • Tazzyman S, Stewart GR, Yeomans J, Linford A, Lath D, Conner J, Muthana M, Chantry AD & Lawson MA (2023) . Viruses, 15(3).
  • Tippett VL, Tattersall L, Ab Latif NB, Shah KM, Lawson MA & Gartland A (2023) . Oncogene, 42(4), 259-277.
  • Diaz-delCastillo M, Nemler T, Thygesen DM, Chávez-Saldaña NA, Vázquez-Mora JA, Palasca O, Juhl L, Evans H, Andrews RE, Mandal A , Chantry AD et al (2022) . Clinical Lymphoma Myeloma and Leukemia, 22, S108-S108.
  • Tattersall L, Shah KM, Lath DL, Singh A, Down JM, De Marchi E, Williamson A, Di Virgilio F, Heymann D, Adinolfi E , Fraser WD et al (2021) . Journal of Bone Oncology, 31.
  • Stewart G, Chantry A & Lawson M (2021) . Cancers, 13(22).
  • Andrews RE, Brown JE, Lawson MA & Chantry AD (2021) . Journal of Clinical Medicine, 10(17).
  • Ottewell PD & Lawson MA (2021) . Journal of Cancer Metastasis and Treatment, 7.
  • Müller LME, Migneco G, Scott GB, Down J, King S, Askar B, Jennings V, Oyajobi B, Scott K, West E , Ralph C et al (2021) . Journal for ImmunoTherapy of Cancer, 9(3).
  • Diaz-delCastillo M, Chantry AD, Lawson MA & Heegaard A-M (2021) . Seminars in Cell & Developmental Biology, 112, 49-58.
  • Marino S, Carrasco G, Li B, Shah KM, Lath DL, Sophocleous A, Lawson MA & Idris AI (2020) . Calcified Tissue International, 107(1), 72-85.
  • Crawford LJ, Campbell DC, Morgan JJ, Lawson MA, Down JM, Chauhan D, McAvera RM, Morris TC, Hamilton C, Krishnan A , Rajalingam K et al (2020) . Oncogene, 39(27), 5001-5014.
  • Diaz-delCastillo M, Kamstrup D, Olsen RB, Hansen RB, Pembridge T, Simanskaite B, Jimenez-Andrade JM, Lawson MA & Heegaard A-M (2020) . JBMR Plus, 4(2).
  • Green AC, Lath D, Hudson K, Walkley B, Down JM, Owen R, Evans HR, Paton‐Hough J, Reilly GC, Lawson MA & Chantry AD (2019) . Journal of Bone and Mineral Research, 34(12), 2311-2326.
  • Legge CJ, Colley HE, Lawson MA & Rawlings AE (2019) . Journal of Oral Pathology & Medicine, 48(9), 803-809.
  • Faraahi Z, Baud'huin M, Croucher PI, Eaton C & Lawson MA (2019) . Bone, 124, 166-166.
  • Faraahi Z, Baud'huin M, Croucher PI, Eaton C & Lawson MA (2019) . Bone, 122, 82-92.
  • Paton-Hough J, Tazzyman S, Evans H, Lath D, Down JM, Green AC, Snowden JA, Chantry AD & Lawson MA (2019) . Journal of Bone and Mineral Research, 34(5), 783-796.
  • Stewart GR, Tazzyman S, Lath D, Down J, Snowden JA, Lawson M, Muthana M & Chantry AD (2018) . Blood, 132(Supplement 1), 3213-3213.
  • Lath DL, Buckle CH, Evans HR, Fisher M, Down JM, Lawson MA & Chantry AD (2018) . PLoS One, 13(6).
  • Ring ES, Lawson MA, Snowden JA, Jolley I & Chantry AD (2018) . Calcified Tissue International, 102(2), 196-209.
  • Lawson MA, Ebetino FH, Mazur A, Chantry AD, Paton-Hough J, Evans HR, Lath D, Tsoumpra MK, Lundy MW, Dobson RLM , Quijano M et al (2017) . Journal of Bone and Mineral Research, 32(9), 1860-1869.
  • Chinnaiya K, Lawson MA, Thomas S, Haider MT, Down J, Chantry AD, Hughes D, Green A, Sayers JR, Snowden JA & Zeidler MP (2017) . Haematologica, 102(6).
  • Evans HR, Karmakharm T, Lawson MA, Walker RE, Harris W, Fellows C, Huggins ID, Richmond P & Chantry AD (2016) . Bone, 83, 9-16.
  • Lawson MA, McDonald MM, Kovacic N, Khoo WH, Terry RL, Down J, Kaplan W, Paton-Hough J, Fellows C, Pettitt JA , Dear TN et al (2015) . Nature Communications, 6.
  • Wang N, Docherty F, Brown HK, Reeves K, Fowles A, Lawson M, Ottewell PD, Holen I, Croucher PI & Eaton CL (2015) . FASEB Journal, 29(8), 3141-3150.
  • Paton-Hough J, Chantry AD & Lawson MA (2015) . Bone, 77, 57-68.
  • Lawson MA, Paton-Hough JM, Evans HR, Walker RE, Harris W, Ratnabalan D, Snowden JA & Chantry AD (2015) . PLOS ONE, 10(3).
  • Walker RE, Lawson MA, Buckle CH, Snowden JA & Chantry AD (2014) . British Medical Bulletin, 111(1), 117-138.
  • Buckle CH, De Leenheer E, Lawson MA, Yong K, Rabin N, Perry M, Vanderkerken K & Croucher PI (2012) . PLoS One, 7(8), e41127.
  • Vitovski S, Chantry AD, Lawson MA & Croucher PI (2012) . PLoS One, 7(5), e35830.
  • Lawson MA, Ashcroft J & Croucher PI (2010) . Curr Pharm Des, 16(27), 3028-3036.
  • Bassett JHD, Boyde A, Howell PGT, Bassett RH, Galliford TM, Archanco M, Evans H, Lawson MA, Croucher P, Germain DLS , Galton VA et al (2010) . P NATL ACAD SCI USA, 107(16), 7604-7609.
  • Buckle CH, Neville-Webbe HL, Croucher PI & Lawson MA (2010) . Curr Pharm Des, 16(11), 1272-1283.
  • Lawson MA, Xia Z, Barnett BL, Triffitt JT, Phipps RJ, Dunford JE, Locklin RM, Ebetino FH & Russell RGG (2010) . Journal of Biomedical Materials Research Part B: Applied Biomaterials, 92B(1), 149-155.
  • Powell F, Lawson M, Rothwell L & Kaiser P (2009) . Developmental & Comparative Immunology, 33(4), 540-546.
  • Lawson MA, Coulton L, Ebetino FH, Vanderkerken K & Croucher PI (2008) . Biochem Biophys Res Commun, 377(2), 453-457.
  • Vanderkerken K, Medicherla S, Coulton L, De Raeve H, Willems A, Lawson M, Van Camp B, Protter AA, Higgins LS, Menu E & Croucher PI (2007) . Cancer Research, 67(10), 4572-4577.
  • Lawson MA, Xia Z, Triffitt JT, Ebetino FH, Phipps RJ & Russell RGG (2006) . Bone, 38(3), 55-55.
  • Xia Z, Lawson MA, Triffitt JT, Ebetino FH, McKenna CE, Marma M, Kashimirov B & Russell RGG (2006) . Bone, 38(3), 63-64.
  • Lawson MA (2006) Driving sound science leadership. FOOD TECHNOLOGY, 60(2), 11-11.
  • Lawson MA (2006) Engaging our younger members. FOOD TECHNOLOGY, 60(5), 11-11.
  • Lawson MA (2006) Perfecting the partnership paradigm. FOOD TECHNOLOGY, 60(3), 11-11.
  • Barralet JE, Wang L, Lawson M, Triffitt JT, Cooper PR & Shelton RM (2005) . Journal of Materials Science: Materials in Medicine, 16(6), 515-519.
  • Lawson MA, Barralet JE, Wang L, Shelton RM & Triffitt JT (2004) . Tissue Engineering, 10(9-10), 1480-1491.
  • Lawson MA, Barralet JE, Wang L, Shelton RM & Triffitt JT (2004) . Tissue Engineering, 10(9), 1480-1491.
  • Wang L, Shelton RM, Cooper PR, Lawson M, Triffitt JT & Barralet JE (2003) . Biomaterials, 24(20), 3475-3481.
  • Vanrompay D, Cox E, Kaiser P, Lawson S, Van Loock M, Volckaert G & Goddeeris B (2001) . Immunology, 103(1), 106-112.
  • Lawson S, Rothwell L, Lambrecht B, Howes K, Venugopal K & Kaiser P (2001) . Developmental & Comparative Immunology, 25(1), 69-82.
  • Lawson S, Rothwell L & Kaiser P (2000) . Journal of Interferon & Cytokine Research, 20(2), 161-170.
  • Evans SR, Korch GW & Lawson MA (1990) . Journal of Medical Entomology, 27(5), 829-834.
  • Lawson MA, Lieske CN, Fox-Talbot MK & Meyer HG (1985) . Life Sciences, 36(18), 1715-1720.
  • Rutledge LC, Lawson MA & Young LL (1982) . Journal of Medical Entomology, 19(4), 361-365.
  • RUTLEDGE LC, LAWSON MA, YOUNG LL & MOUSSA MA (1981) NON-CORRELATION OF INSECTICIDE AND REPELLENT TOLERANCES IN REPRESENTATIVE SPECIES AND STRAINS OF MOSQUITOS. MOSQUITO NEWS, 41(4), 684-688.
  • Rutledge LC, Moussa MA, Zeller BL & Lawson MA (1979) . Journal of Medical Entomology, 15(5-6), 452-458.
  • RUTLEDGE LC, LAWSON MA, YOUNG LL & MOUSSA MA (1979) REARING OF DIAMANUS-MONTANUS (SIPHONAPTERA, CERATOPHYLLIDAE) AND HOPLOPSYLLUS-ANOMALUS (SIPHONAPTERA, PULICIDAE). JOURNAL OF MEDICAL ENTOMOLOGY, 15(3), 303-303.
  • Weeks MH, Lawson MA, Angerhofer RA, Davenport CD & Pennington E (1977) . Archives of Environmental Contamination and Toxicology, 6(1), 23-31.
  • Feldman WM & Lawson MA (1924) A case of "congenital " occlusion of the common hepatic duct in a twin baby, with an indirect van den Berg reaction. LANCET, 2, 113-113.
  • Lawson M, Chantry A, Paton-Hough J, Evans H, Lath D, Tsoumpra M, Lundy M, Dobson R, Quijano M, Kwaasi A , Dunford J et al () . Bone Abstracts.
  • Buckle C, Faraahi Z, Lawson M, Eaton C, Vanderkerken K & Croucher P () . Bone Abstracts.

Book chapters

  • Holen I, Saleh L, Ottewell PD & Lawson MA (2022) , Bone Cancer (pp. 35-53). Elsevier
  • Edwards CM & Lawson MA (2022) , Bone Cancer (pp. 1005-1017). Elsevier
  • Green AC, Andrews RE & Lawson MA (2020) , Encyclopedia of Bone Biology (pp. 180-200). Elsevier
  • Russell RGG, Tsoumpra MK, Lawson MA, Chantry AD, Ebetino FH & Pazianas M (2016) , The Duration and Safety of Osteoporosis Treatment (pp. 17-36). Springer International Publishing
  • Alix-Panabieres C, Arlt MJE, Bataille R, Bedard G, Berthold DR, Bianco P, Blanchard F, Blay J-Y, Bolton D, Bolzoni M , Born W et al (2015) , Bone Cancer (pp. xi-xv). Elsevier
  • Holen I & Lawson MA (2015) , Bone Cancer (pp. 503-518). Elsevier
  • Holen I & Lawson MA (2015) , Bone Cancer Primary Bone Cancers and Bone Metastases Second Edition (pp. 503-518).
  • Holen I & Lawson MA (2010) , Bone Cancer (pp. 347-363).
  • Ando K, Arslandemir C, Bell WC, Berdal A, Berthold D, Bhat BM, Bhat RA, Bhattacharyya S, Billiard J, Blanchard F , Bodine PVN et al (2010) , Bone Cancer (pp. xi-xv). Elsevier
  • Holen I & Lawson MA (2010) , Bone Cancer (pp. 347-363). Elsevier

Conference proceedings

  • Diaz-DelCastillo M, Nemler T, Thygesen DM, Chavez-Saldana NA, Vazquez-Mora JA, Palasca O, Juhl L, Evans H, Andrews RE, Mandal A , Chantry AD et al (2023) Mechanisms of Bone Pain in Multiple Myeloma: Involvement of Periosteal Bone Sprouting. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 38 (pp 55-56)
  • Diaz-delCastillo M, Nemler T, Thygesen DM, Chavez-Saldana NA, Vazquez-Mora JA, Palasca O, Juhl L, Evans H, Andrews RE, Mandal A , Chantry AD et al (2022) Myeloma-induced bone pain: lessons learnt from a localized, immunocompetent mouse model. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, Vol. 22 (pp S108-S108)
  • Stewart G, Tazzyman ST, Lath D, Down J, Lawson M, Muthana M & Chantry A (2019) Myeloma-specific oncolytic adenovirus induces significant tumour oncolysis in vitro and in vivo and prevents cell line regrowth. BRITISH JOURNAL OF HAEMATOLOGY, Vol. 185 (pp 97-97)
  • Paton-Hough J, Lawson M & Chantry A (2019) Preventing and repairing myeloma bone disease by combining zoledronic acid with TGFβ inhibition therapy. BRITISH JOURNAL OF HAEMATOLOGY, Vol. 185 (pp 16-16)
  • Jiang Y, Down J, Raffles S, Jenkins E, Ferretti L, Bunce C, Drayson M, Lawson M & Khanim F (2018) . Experimental Hematology, Vol. 64(Suppl) (pp S74-S75). Los Angeles, USA, 23 August 2018 - 26 August 2018.
  • Tattersall L, De Marchi E, Williamson A, Di VF, Lawson MA, Adinolfi E & Gartland A (2018) P2X7R in primary bone cancer. PURINERGIC SIGNALLING, Vol. 14 (pp S13-S14)
  • Müller LME, Parrish C, Migneco G, Scott GB, Holmes M, Melcher AA, Lawson MA, Cook G & Errington-Mais F (2017) . Clinical Cancer Research, Vol. 23(24_Supplement) (pp 18-18)
  • Mueller LME, Parrish C, Migneco G, Scott GB, Holmes M, Melcher AA, Lawson MA, Cook G & Errington-Mais F (2017) . Clinical Cancer Research, Vol. 23(24) (pp 18). Boston, MA, 6 May 2017 - 6 May 2017.
  • Williams AJ, Lawson MA, Alamer O, Hough J, Bos T, Vanderkerken K & Croucher PI (2011) . BONE, Vol. 48(1) (pp S14-S14)
  • Vitovski S, Chantry AD, Lawson MA & Croucher PI (2011) . BONE, Vol. 48(1) (pp S15-S15)
  • Williams A, Lawson M, Bos T, Amani E, Hough J, Evans H, Lath D, Gallagher O, Coulton L, Vanderkerken K & Croucher P (2010) . BONE, Vol. 47 (pp S328-S328)
  • Buckle CH, De Leenheer E, Lawson MA, Hough JM, Yong KL, Rabin N, Vanderkerken K & Croucher PI (2009) . BONE, Vol. 44 (pp S162-S162)
  • Lawson MA, Williams AJ, Bos T, Vanderkerken K & Croucher PI (2009) . BONE, Vol. 44 (pp S164-S164)
  • Xia Z, Dunford J, Lawson MA, Triffitt JT, Kavanagh K, Oppermann U, Barnett BL, Ebetino FH & Russell RGG (2007) Nitrogen-containing bisphosphonates and prediction of their clinical potencies: Dissociation of target enzyme- and hydroxyapatite-binding affinities. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 22(7) (pp 1125-1125)
  • Xia Z, Dunford J, Lawson MA, Triffitt JT, Kavanagh K, Oppermann U, Roze C, Kashemirov B, McKenna CE, Ebetino FH & Russell RG (2007) Predicting pharmacological potencies of nitrogen-containing bisphosphonates; novel methods dissociate enzyme- and hydroxyapatite-binding affinities. BONE, Vol. 40(6) (pp S301-S302)
  • Xia Z, Dunford J, Lawson MA, Triffitt JT, Barnett BL, Ebetino FH & Russell RGG (2007) Predicting the clinical potencies of bisphosphonates: Divergence of hydroxyapatite and farnesyl diphosphate synthase binding affinities. CALCIFIED TISSUE INTERNATIONAL, Vol. 80 (pp S155-S155)
  • Lawson MA, Coulton L, Ebetino FH, Gallagher O, Prideaux M, Vanderkerken K & Croucher PI (2006) Risedronate prevents bone disease and reduces turnour burden in a syngeneic model of multiple myeloma.. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 21 (pp S137-S137)
  • Lawson MA, Coulton L, Ebetino FH, Gallagher O, Prideaux M, Vanderkerken K & Croucher PI (2006) Risedronate prevents bone disease and reduces tumour burden in a syngeneic model of multiple myeloma. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 21(7) (pp 1160-1160)
  • Lawson MA, Coulton L, Ebetino FH, Gallagher O, Prideaux M, Vanderkerken K & Croucher P (2006) Risedronate prevents bone disease and reduces tumour burden in a syngeneic model of multiple myeloma. CANCER TREATMENT REVIEWS, Vol. 32 (pp S35-S35)
  • Xia Z, Dunford J, Lawson MA, Triffitt JT, Barnett BL, Roze C, Kashemirov B, McKenna CE, Ebetino FH & Russell RGG (2006) Refining structure activity relationships among nitrogen containing bisphosphonates: Dissociation of mineral binding affinity and inhibitory potency on farnesyl diphosphate synthase.. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 21 (pp S183-S183)
  • Xia Z, Lawson MA, Triffitt JT, Ebetino FH, McKenna CE, Marma M, Kashemirov B & Russell RGG (2006) A novel method to characterize relative mineral binding affinities of bisphosphonates and the structural requirements for binding by using ceramic hydroxyapatite column chromatography.. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 21 (pp S191-S191)
  • Xia ZT, Triffitt JT, Lawson MA, Ebetino H, McKenna CE, Marma M, Kashimirov B & Russell RGG (2006) Substitutions in the R1 hydroxyl and C1 phosphate positions significantly affect binding of risedronate during hydroxyapatite ceramic chromatography. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 21(7) (pp 1168-1168)
  • Lawson MA, Triffitt JT, Ebetino FH, Barnett BL, Phipps RJ, Locklin RM & Russell RGG (2005) Potential bone mineral binding differences among bisphosphonates can be demonstrated by the use of hydroxyapatite column chromatography.. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 20(9) (pp S396-S396)
  • Lawson MA, Triffitt JT, Ebetino FH, Phipps RJ, White DJ & Russell RGG (2005) The use of hydroxyapatite column chromatography as a novel method to reveal differences in relative binding affinities of bisphosphonates. BONE, Vol. 36 (pp S308-S309)
  • Lawson MA, Triffitt JT, Ebetino FH, Barnett BL, Phipps RJ, White DJ & Russell RGG (2005) Differences in the potential binding of phosphate containing compounds to bone mineral are revealed by the novel use of hydroxyapatite column chromatography. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 20(7) (pp 1303-1303)
  • Wang L, Barralet JE, Lawson M, Triffitt JT, Cooper PC & Shelton RM (2004) Comparison of 2D and 3D bone marrow cell growth on alginate hydrogels. Transactions 7th World Biomaterials Congress (pp 154)
  • Lawson MA, Wang L, Shelton RM, Barralet JE & Triffitt JT (2004) Behaviour of bone marrow stromal cells on and within alginate gels for potential use in tissue engineering procedures. Transactions 7th World Biomaterials Congress (pp 913)
  • LAWSON MA, DAVIS WR, BURGARD SL & ROGERS WJ (1994) PREDICTORS OF MORTALITY AT HOSPITAL DISCHARGE AND AT ONE-YEAR FOR PATIENTS PRESENTING TO TERTIARY CARE HOSPITALS WITH MYOCARDIAL-INFARCTION. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (pp A296-A296)
  • JOHNSON LL, BLACKWELL GG, LAWSON MA, TAUXE EL, RUSSELL KL, DELLITALIA LJ & POHOST GM (1994) OPTIMIZING THE METHOD TO CALCULATE RIGHT-VENTRICULAR EJECTION FRACTION FROM 1ST PASS DATA. CIRCULATION, Vol. 90(4) (pp 365-365)
  • ALAMI M, LAWSON MA, TAUXE EL, JOHNSON L, BLACKWELL GG, DELLITALIA LJ & POHOST GM (1994) CORRELATION OF THALLIUM UPTAKE WITH LEFT-VENTRICULAR WALL THICKNESS BY CINE MRI IN PATIENTS WITH MYOCARDIAL INFARCTIONS. CIRCULATION, Vol. 90(4) (pp 365-365)
  • LAWSON MA, BLACKWELL GG, DELLITALLA LJ, DAVIS ND & POHOST GM (1994) ACCURACY OF BIPLANE LONG AXIS CINE MRI VOLUMES IN PATIENTS WITH REGIONAL AND GLOBAL LEFT-VENTRICULAR DYSFUNCTION. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (pp A90-A90)
  • LAWSON MA, WALSH EG, DOYLE M, BLACKWELL GG, JOHNSON LL & POHOST GM (1994) MULTISLICE MRI IN THE ASSESSMENT OF MYOCARDIAL PERFUSION - A COMPARISON WITH RADIONUCLIDE METHODS. CIRCULATION, Vol. 90(4) (pp 411-411)
  • KAPLAN AM, LAWSON MA, BONSTELLE CT & WODRICH DL (1994) POSITRON EMISSION TOMOGRAPHY IN CHILDREN WITH NEUROFIBROMATOSIS-1. ANNALS OF NEUROLOGY, Vol. 36(3) (pp 543-543)
  • LAWSON MA, DAVIS WR, BURGARD SL & ROGERS WJ (1993) DO PREDICTORS OF MORTALITY AT ONE-YEAR DIFFER FROM THOSE AT HOSPITAL DISCHARGE FOR PATIENTS PRESENTING WITH MYOCARDIAL-INFARCTION. CLINICAL RESEARCH, Vol. 41(4) (pp A781-A781)
  • CASELLI RJ, REIMAN EM, LAWSON MA, OSBORNE D & MOORE SB (1993) GENETIC-FACTORS IN ASYMMETRICAL CORTICAL DEGENERATION - A POSITRON EMISSION TOMOGRAPHY STUDY IN CLINICALLY DISCORDANT IDENTICAL-TWINS. ANNALS OF NEUROLOGY, Vol. 34(2) (pp 293-293)
  • LAWSON MA, DAVIS WR, BURGARD SL & ROGERS WJ (1992) HISTORICAL AND CLINICAL PREDICTORS OF IN-HOSPITAL DEATH AND REINFARCTION IN PATIENTS PRESENTING WITH PROLONGED CHEST PAIN. CLINICAL RESEARCH, Vol. 40(4) (pp A805-A805)
  • MIURA GA, BROOMFIELD CA, LAWSON MA & WORTHLEY EG (1982) WIDESPREAD DISTRIBUTION OF CHOLINESTERASE ACTIVITY IN GREEN PLANTS. FEDERATION PROCEEDINGS, Vol. 41(4) (pp 1146-1146)
  • LAWSON MA, LIESKE CN, FEROLI SL, GANDHI PK & MEYER HG (1982) SPONTANEOUS REACTIVATION OF HUMAN-SERUM CHOLINESTERASE INHIBITED BY SELECTED ORGANOPHOSPHINATES. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, Vol. 183(MAR) (pp 15-MEDI)
  • LAWSON MA & KISER SR (1974) GENERAL APPLICATIONS OF PROGRAMMABLE DESK TOP CALCULATOR. JOURNAL OF NUCLEAR MEDICINE, Vol. 15(6) (pp 511-511)

Other

  • Harrop R, Blount DG, Khan N, Soyombo M, Moyce L, Drayson MT, Down J, Lawson MA, O’Connor D, Nimmo R , Lad Y et al (2025) .
  • Harrop R, Blount DG, Khan N, Soyombo M, Moyce L, Drayson MT, Down J, Lawson MA, O’Connor D, Nimmo R , Lad Y et al (2025) .
  • Harrop R, Blount DG, Khan N, Soyombo M, Moyce L, Drayson MT, Down J, Lawson MA, O’Connor D, Nimmo R , Lad Y et al (2025) .
  • Harrop R, Blount DG, Khan N, Soyombo M, Moyce L, Drayson MT, Down J, Lawson MA, O’Connor D, Nimmo R , Lad Y et al (2025) .
  • Harrop R, Blount DG, Khan N, Soyombo M, Moyce L, Drayson MT, Down J, Lawson MA, O’Connor D, Nimmo R , Lad Y et al (2025) .
  • Harrop R, Blount DG, Khan N, Soyombo M, Moyce L, Drayson MT, Down J, Lawson MA, O’Connor D, Nimmo R , Lad Y et al (2025) .
  • Harrop R, Blount DG, Khan N, Soyombo M, Moyce L, Drayson MT, Down J, Lawson MA, O’Connor D, Nimmo R , Lad Y et al (2025) .

Preprints

  • Jiang Y, Down JM, Maynard S, Jenkins S, Ferritti L, Beke F, Al-Hazmi B, Southam AD, Kvist J, Mirbahai L , Besse L et al (2023) , Research Square Platform LLC.
  • Diaz-delCastillo M, Palasca O, Nemler TT, Thygesen DM, Chávez-Saldaña NA, Vázquez-Mora JA, Ponce Gomez LY, Jensen LJ, Evans H, Andrews RE , Mandal A et al (2022) , Cold Spring Harbor Laboratory.
  • Tattersall L, Shah KM, Lath DL, Singh A, Down JM, De Marchi E, Williamson A, Di Virgilio F, Heymann D, Adinolfi E , Fraser WD et al (2021) , Cold Spring Harbor Laboratory.
Grants
  1. Innovate UK award (UK Biomedical Catalyst 2022-2025) Preclinical validation of a novel oncolytic viral therapy for multiple myeloma targeting readiness for clinical trials. Dr M.A. Lawson & Dr A.D. Chantry (£127,545).&Բ;10017183
  2. Sheffield Hospitals Charity Project Award (2021-2022). Treating plasmacytoma using direct injection of a novel engineered myeloma specific virus. Dr M.A. Lawson (£24,275). No. 173173
  3. Sheffield Hospitals Charity Project Award (2021-2022). The effect of targeting hepatocyte growth factor (HGF) combined with chemotherapy on tumour load in myeloma. Dr M.A. Lawson (£13,891). No. 173345
  4. NC3Rs studentship award (2021-2023). Development and validation of 3D in vitro dormant myeloma cell models to reduce and replace animal studies. Dr M.A. Lawson, Alana Green & Frederik Claeyssens (£90,000). NC/V00137X/1
  5. Sheffield Hospitals Charity Project Award (2021-2022). Targeting minimal residual disease to find a cure for myeloma. Dr A. Green, Dr A.D. Chantry, Dr M.A. Lawson (£42,862). No. 169591
  6. Sheffield Hospitals Charity Project Award (2020-2021). Assessing SD208 (a novel bone anabolic agent) as equivalent or superior in the treatment of myeloma bone; an in vivo explorative study. Dr R. Andrews, Dr Chantry & Dr M.A. Lawson (£41,000). 163969
  7. Sheffield Hospitals Charity Project Award (2020-2021). Oncolytic advenovirus therapy for multiple myeloma. Dr Chantry & Dr M.A. Lawson (£41,143). No. 202014
  8. Oxford Biomedica (2019-2020) Clinical collaboration using CAR-T cells therapy. Dr M. A. Lawson (£13,400).
  9. Shin Poong Pharma (2017-2018). Testing a potential bone anabolic agent (SP-35454) in multiple myeloma, Dr M. A. Lawson (£140,000).
  10. Bone Cancer Research Trust (2015-2018). PhD studentship: Purinergic Signalling in Osteosarcoma, Dr A. Gartland & Dr M.A. Lawson (£147,000). BCRT Grant No. 44/15.
  11. British Association of Oral and Maxillofacial Surgeon (2106-218) Project Grant: Investigating the potential of statins to prevent and treat Anti-Resorptive agent induced Osteonecrosis of the Jaw, Dr M. A. Lawson, Ibraz Siddique & Alasdair McKechnie (£6384).
  12. Sheffield Blood Cancer Trust (2015). High potency, low affinity bisphosphonates pilot study, Dr A. Chantry, Dr M.A. Lawson, Prof. J. Snowden& Prof R.G.G. Russell (£8,000).
  13. Sheffield Hospitals Charity (2015). Investigating changes in the tumour bone microenvironment during the development of multiple myeloma and testing novel strategies for clinical intervention. Dr M.A. Lawson, J. Paton-Hough (Sheffield) & Dr F. Errington-Mais (University of Leeds) (£4,739).
  14. Bloodwise Project Grant (2018-2020). Targeting BMP signalling in the MGUS/MM bone microenvironment. Dr C. Edwards, Dr K. Ramasamy, Dr M.A. Lawson, H. Drakesmith, Dr S. Gooding & R. Kumar grant (£249,691). Grant no. 17012.
  15. Bloodwise Project Grant Investigating (2016-2019). E3 Ligase HUWE1 as a therapeutic target in multiple myeloma.Dr A. Irvine, Dr M.A. Lawson, M. Pearson, Dr L. Crawford, Prof M. Eilers & Dr A. Chantry (£202,080). Grant no. 15043.
  16. Bloodwise Project Grant (2015-2018). Preclinical testing of low dose valproate and niclosamide (VaN) as a novel anti-myeloma therapy. Dr F. Khanim, Dr M.A. Lawson& Prof. M Drayson (£245,864). Grant No. 15025.
  17. Bloodwise Specialist Programme Grant (2013-2018). Novel targets and therapeutic combinations in myeloma. Dr A. Chantry, Dr M.A. Lawson & Prof. J. Snowden (£1,142,591). Grant No. 12053.
Teaching interests

I am a Fellow of the Higher Education Academy (FHEA) and the Postgraduate Research (PGR) Lead in the Department of Oncology and Metabolism. I am also a Module Lead for the MSc (Res) in Translational Oncology course and I regularly lecture on the Molecular Medicine MSc course on in vitro and in vivo models of bone cancer. I frequently supervise laboratory research projects for PhD, MSc, BMedSci, SSC, Erasmus and Hallam placement students.

Professional activities and memberships

I have been involved in several public engagement activities. I have secured funding that enabled me to build a “Giant Interactive Bone” to educate children of all ages on what is inside their bones. In addition, I regularly participate in Outreach activities with a variety of school children to teach them about why their bones are so important. I frequently do laboratory tours for fundraisers and patients with bone cancer, and I also participate in patient panel meetings to improve the services at the Royal Hallamshire Hospital in Sheffield.

Public engagement activities

I have also been involved in a number of public engagement activities. I have secured funding that enabled me to build a “Giant Interactive Bone” to educate children of all ages on what is inside their bones. In addition, I regularly participate in Outreach activities with a variety of school children to teach them about why their bones are so important. I frequently do laboratory tours for fundraisers and patients with bone cancer, and I also participate in patient panel meetings to improve the services at the Royal Hallamshire Hospital in Sheffield.